Ginkgo Bioworks buys North Carolina startup’s gene therapy platform


The future of a North Carolina-based gene therapy company founded by a Duke University professor is unclear now that it has sold its main platform.

Previous Cash-rich life sciences companies are targets. Activist investors are taking aim.
Next Provation CEO Daniel Hamburger retires, Ankush Kaul appointed president